CLL and small lymphocytic lymphoma (SLL) are the disease in which BTK inhibitors have been more extensively employed, both in the relapsed and refractory setting and in treatment‐naïve patients, across the entire spectrum of cytogenetic and molecular risk features. Here, BTK is linked to B-cell chronic lymphocytic leukemia.